Figure 1.

TET2 CHIP is associated with increased risk of incident AF in UK Biobank. A total of 358 097 individuals from the UK Biobank with available whole-exome sequencing were identified. Prevalent hematological malignancies, valvular heart disease, HF, and prevalent AF were excluded. Cox proportion hazard models adjusted for age, age², sex, ever-smoked status, genetic ancestry (European/non-European), BMI, prevalent type 2 diabetes (T2D), prevalent hypertension, prevalent coronary artery disease (CAD), LDL (adjusted for statin use), as previously described.¹⁵ Individuals with AF, T2D, hypertension, CAD, HF, valvular disease, and hematological malignancies were identified on the basis of International Classification of Diseases, Ninth and 10th Revisions, codes. A and B, Increased cumulative incidence of AF in individuals with CHIP ≥0.1, with HR 1.132 (95% CI, 1.049–1.222; P=0.00142). C, Increased cumulative incidence of AF in patients with TET2 CHIP ≥0.1 with HR 1.27 (95% CI, 1.077–1.498; P=0.00442). AF indicates atrial fibrillation; ASXL1, additional sex combs-like 1; BMI, body mass index; CHIP, clonal hematopoiesis of indeterminate potential; DNMT3A, DNA (cytosine-5)-methyltransferase 3A; HF, heart failure; HR, hazard ratio; LDL, low-density lipoprotein; TET2, tet methylcystosine dioxygenase 2; and VAF, variant allele frequency.